Tag Archives: ARGX-113

Netherlands-based, emerging biotech star arGEN-X gives shareholders two doses of great news; stock skyrockets.

The News: arGEN-X SE (Breda NLD) has smoked its target of $150 million for a US stock offering, which will support its cancer and autoimmune disease antibodies through the clinical phases…. Read more »